NCT06394804View on ClinicalTrials.gov

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Low-Grade Serous Ovarian Cancer
Interventions
DRUG

Avutometinib

Starting Dose 3.2 mg BIW for 3 of 4 weeks, Dose -1, 2.4 mg BIW for 3 of 4 weeks

DRUG

Defactinib

Starting Dose 200 mg BID for 3 of 4 weeks, Dose -1, 200 mg QD for 3 of 4 weeks

DRUG

Letrozole

2.5 mg PO daily

Trial Locations (8)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack

30322

RECRUITING

Emory Winship Cancer Institute, Atlanta

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

Verastem, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER